These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 17720276)

  • 1. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A; Trojan A; Burnand B; Giannelli M
    Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
    Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    de Castria TB; da Silva EM; Gois AF; Riera R
    Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
    Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
    Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A meta-analysis of the curative effects of carboplatin-based and cisplatin-based chemotherapeutic regimens on advance non-small cell lung cancer].
    Jiang JW; Liang XH; Zhou XL; Huang RF
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(37):2615-20. PubMed ID: 17198587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; de Castria TB; Cruz MR; Riera R
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
    D'Addario G; Pintilie M; Leighl NB; Feld R; Cerny T; Shepherd FA
    J Clin Oncol; 2005 May; 23(13):2926-36. PubMed ID: 15728229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.
    Luo L; Hu Q; Jiang JX; Yang X; Dinglin XX; Lin X; Yao HR
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):253-61. PubMed ID: 25866140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
    Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
    Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.
    Yu J; Xiao J; Yang Y; Cao B
    Medicine (Baltimore); 2015 Jul; 94(27):e1072. PubMed ID: 26166081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
    Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
    Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
    J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
    Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
    Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
    Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
    J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.